Compounds > 7-hydroxy-6-methyl-8-(1-d-ribityl)lumazine
Page last updated: 2024-09-27
7-hydroxy-6-methyl-8-(1-d-ribityl)lumazine
Description
photolumazine C: inhibitor of riboflavin synthetase; isolated from Photobacterium phosphoreum; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
6-methyl-7-oxo-8-(1-D-ribityl)lumazine (2-oxo tautomer) : A D-ribityl derivative of pteridine that is a potent inhibitor of riboflavin synthetase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
6-methyl-7-oxo-8-(1-D-ribityl)lumazine (2-hydroxy tautomer) : A pteridine that is lumazine substituted by methyl and oxo groups at C-6 and -7 respectively as well as a 1-D-ribityl group on N-8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
7-hydroxy-6-methyl-8-(1-D-ribityl)lumazine : The pteridine that is lumazine substituted with a methyl group at C-6, a hydroxy group at C-7 and a 1-D-ribityl group at N-8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 440869 |
| CHEBI ID | 60900 |
| CHEBI ID | 27581 |
| CHEBI ID | 73090 |
| SCHEMBL ID | 15603800 |
| SCHEMBL ID | 11754109 |
| MeSH ID | M0052068 |
Synonyms (28)
| Synonym |
|---|
| CHEBI:60900 |
| 1-deoxy-1-(6-methyl-2,4,7-trioxo-1,3,4,7-tetrahydropteridin-8(2h)-yl)-d-ribitol |
| 6-methyl-7-oxo-8-(1-d-ribityl)lumazine (2-oxo tautomer) |
| photolumazine c |
| 6-methyl-7-oxo-8-ribityllumazine |
| C05995 |
| 7-hydroxy-6-methyl-8-ribityllumazine |
| 6-methyl-8-[(2s,3s,4r)-2,3,4,5-tetrahydroxypentyl]-1h-pteridine-2,4,7-trione |
| masuda's compound v |
| 7-hydroxy-6-methyl-8-d-ribityllumazine |
| 1-deoxy-1-(3,4-dihydro-7-hydroxy-6-methyl-2,4-dioxo-8(2h)-pteridinyl)-d-ribitol |
| 7-hydroxy-6-methyl-8-(1-d-ribityl)lumazine |
| rl-6-me-7-oh |
| CHEBI:27581 , |
| 1-deoxy-1-(7-hydroxy-6-methyl-2,4-dioxo-3,4-dihydropteridin-8(2h)-yl)-d-ribitol |
| 7-hydroxy-6-methyl-8-ribityl lumazine |
| 6-methyl-7-oxo-8-(1-d-ribityl)lumazine (2-hydroxy tautomer) |
| CHEBI:73090 |
| 1-deoxy-1-(2-hydroxy-6-methyl-4,7-dioxo-1,7-dihydropteridin-8(4h)-yl)-d-ribitol |
| 1vy , |
| EPITOPE ID:178095 |
| 4L4V |
| SCHEMBL15603800 |
| SCHEMBL11754109 |
| QCYVUUAIJUUUPI-BBVRLYRLSA-N |
| Q27103208 |
| DTXSID701289963 |
| 6-methyl-7-hydroxy-8-ribityllumazine |
Roles (1)
| Role | Description |
|---|
| EC 2.5.1.9 (riboflavin synthase) inhibitor | An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that inhibits the action of riboflavin synthase (EC 2.5.1.9). |
| EC 2.5.1.9 (riboflavin synthase) inhibitor | An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that inhibits the action of riboflavin synthase (EC 2.5.1.9). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| pteridines | |
| pteridines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathways (1)
7-hydroxy-6-methyl-8-(1-d-ribityl)lumazine is involved in 1 pathway(s), involving a total of 5 unique proteins and 15 unique compounds
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |